Working... Menu

Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00185445
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : December 4, 2013
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:
The purpose of the study is to demonstrate that oral fludarabine phosphate is comparable to i.v. formulation used in combination with mitoxantrone in terms of efficacy, safety and risk/benefit profile

Condition or disease Intervention/treatment Phase
Non Hodgkin Lymphoma Drug: Fludarabine Phosphate (Fludara) Phase 2

Detailed Description:
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study to Evaluate the Efficacy and Safety of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL
Study Start Date : June 2004
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Arm Intervention/treatment
Experimental: Arm 1 Drug: Fludarabine Phosphate (Fludara)
All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
Other Name: BAY86-4864

Primary Outcome Measures :
  1. Complete response rate [ Time Frame: Measurement of outcome 4 to 6 weeks after EOT ]

Secondary Outcome Measures :
  1. Overall response rate, molecular response rate, toxicity profile, patients quality of life [ Time Frame: Measurement of outcome 4 to 6 weeks after EOT ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Indolent B-cell follicular non-Hodgkin's lymphoma (grade I-II according to REAL classification)
  • Stage II to IV according to Ann Arbor staging system
  • WHO performance status grade 0, 1 or 2 and life expectancy of greater than 6 months

Exclusion Criteria:

  • Patients who have received any previous treatment for follicular NHL
  • Patients with severe or life-threatening cardiac, pulmonary, neurological, psychiatric or metabolic disease
  • Pregnant and lactating women
  • Women of childbearing potential, and all men, not agreeing to take adequate contraceptive precautions during and for at least 6 months after cessation of therapy
  • Laboratory screens positive for Hepatitis B, C or HIV infections
  • Patients with autoimmune thrombocytopenia or hemolytic anemia with clinical evidence. NB. A positive Coombs test alone (with no clinical evidence of hemolysis) would not preclude entry in the study.
  • Histological transformation to aggressive B-cell lymphoma
  • Patients with prior malignancies except non melanoma skin tumors or stage 0 (in situ) cervical carcinoma
  • Impairment of hepatic function unless disease related indicated by bilirubin, ASAT, ALAT or gamma-GT raised 2 times above the upper limit of the local laboratory range
  • Impairment of renal function indicated by serum creatinine < 30 ml/min
  • Patients who require systemic long-term therapy with glucocorticoids
  • Participation at the same time in another study in which investigational drugs are used
  • Patients unable to regularly attend outpatient clinic for treatment and assessments
  • Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
  • Patients with active infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00185445

Layout table for location information
Bologna, BO, Italy, 40138
Cesena, FC, Italy, 47023
Forlì, FC, Italy, 47100
Genova, GE, Italy, 16132
Roma, RM, Italy, 00144
Roma, RM, Italy, 00168
Rimini, RN, Italy, 47900
Cagliari, Italy, 09121
Firenze, Italy, 50139
Napoli, Italy, 80131
Ravenna, Italy, 48100
Roma, Italy, 00161
Siena, Italy, 53100
Udine, Italy, 33100
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company

Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company Identifier: NCT00185445     History of Changes
Other Study ID Numbers: 308580
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: December 4, 2013
Last Verified: December 2013

Keywords provided by Sanofi ( Genzyme, a Sanofi Company ):
Non Hodgkin Lymphoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Fludarabine phosphate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents
Sensory System Agents
Peripheral Nervous System Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors